Barclays PLC Innate Pharma Sa Transaction History
Barclays PLC
- $436 Billion
- Q2 2025
A detailed history of Barclays PLC transactions in Innate Pharma Sa stock. As of the latest transaction made, Barclays PLC holds 307 shares of IPHA stock, worth $635. This represents 0.0% of its overall portfolio holdings.
Number of Shares
307
Previous 307
-0.0%
Holding current value
$635
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding IPHA
# of Institutions
10Shares Held
99.8KCall Options Held
0Put Options Held
0-
Morgan Stanley New York, NY51.2KShares$106,0330.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il26.6KShares$55,0970.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny11.7KShares$24,1380.0% of portfolio
-
Ubs Group Ag5.96KShares$12,3300.0% of portfolio
-
Gamma Investing LLC Foster City, CA3.46KShares$7,1530.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $165M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...